Mood Emot 2022 Mar; 20(1): 15-22
A Study of Dry Mouth and Gastrointestinal Disorders in Patients Taking Antidepressant
Yeong-Jin Heo, MD1 , Chan-Mo Yang, MD1 , Hye-Jin Lee, PhD2 , Sang-Yeol Lee, MD, PhD1 , Seung-Ho Jang, MD1
1Departement of Psychiatry, School of Medicine, Wonkwang University, 2Department of Public Health, Wonkwang University Graduate School, Iksan, Korea
Correspondence to: Seung-Ho Jang, MD
Department of Psychiatry, School of Medicine, Wonkwang University, 895 Muwang-ro, Iksan 54538, Korea
TEL +82-63-859-1044 FAX +82-857-1043 E-mail ORCID
Received: March 18, 2022; Accepted: March 18, 2022; Published online: March 31, 2022.
© Korean Society for Affective Disorders. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: The purpose of this study was to identify the characteristics of dry mouth and gastrointestinal (GI) disorders in antidepressant patients.
Methods: The study included 103 antidepressant-taking patients. Antidepressants were classified according to their mode of action. The GI disorders were investigated using the medical records of the patients. The Patient Health Questionnaire-15 and a questionnaire for assessing dry mouth symptoms were used in this study.
Results: The score for “overall discomfort due to dry mouth in daily life” (31.72±33.82), “dry mouth at night or in the morning” (47.86±35.87), and “dry mouth during the day” (39.83±31.67) were slightly higher than “discomfort in chewing or swallowing foods”. According to somatization severity, the mean values were 116.36±113.34 in the mild, 213.18±136.98 in the moderate, and 277.59±201.44 in the severe, the between-group difference was significant (F=10.294, p<0.001). According to the class of antidepressants, the mean score was 180.00±147.5 for vortioxetine, 194.25±169.33 for selective serotonin reuptake inhibitors (SSRIs), 223.61±156.70 for serotonin and norepinephrine reuptake inhibitors (SNRIs), 75.00±57.00 for norepinephrine dopamine reuptake inhibitors (NDRIs), 201.67±174.66 for Nassau, and 116.67±132.03 for agomelatine. A total of 67 (65.0%) patients had at least one GI disorder.
Conclusion: The study findings are expected to help increase medication compliance in antidepressant patients by better controlling the side effects experienced by the patients.
Keywords: Dry mouth; Gastrointestinal disorders; Somatization; Antidepressant; Functional dyspepsia

  • Search

This Article

Funding Information

Social Network Service